Progress in rheumatology in the early 21st century

Rheumatoid arthritis (RA), juvenile arthritis, spondyloarthritis, including psoriatic arthritis, systemic lupus erythematosus (SLE), and other systemic connective tissue diseases, are the most severe chronic immunoinflammatory rheumatic diseases (IIRDs) that affect as high as 10% of the population....

Full description

Bibliographic Details
Main Author: E. L. Nasonov
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2014-09-01
Series:Современная ревматология
Subjects:
Online Access:https://mrj.ima-press.net/mrj/article/view/555
_version_ 1826556944607870976
author E. L. Nasonov
author_facet E. L. Nasonov
author_sort E. L. Nasonov
collection DOAJ
description Rheumatoid arthritis (RA), juvenile arthritis, spondyloarthritis, including psoriatic arthritis, systemic lupus erythematosus (SLE), and other systemic connective tissue diseases, are the most severe chronic immunoinflammatory rheumatic diseases (IIRDs) that affect as high as 10% of the population. Substantial progress has been made in the treatment of IIRDs in the 21st century. The current Treat to Target (T2T) strategy for RA is to achieve remission as soon as possible. The main treatment goal is to improve quality of life, by controlling the symptoms of the disease, by preventing joint destruction and dysfunction, and by maintaining social possibilities. The most important way to achieve this goal is to inhibit inflammation and to evaluate the efficiency of treatment, by using the standardized activity indices and by choosing the appropriate treatment option. The widespread use of biological agents in combination with standard disease-modifying antirheumatic drugs could substantially enhance therapeutic effectiveness. A new class of medicaments (chemically synthesized small molecular weight agents) to treat RA has appeared. The point of their application is tyrosine kinases, primarily Janus kinase (JAK). The new era in the treatment of SLE and other IIRDs is associated with the design of the new class of drugs Р BLyS inhibitors. In the coming years, the main lines of researches by Russian rheumatologists will be to elaborate a strategy to prevent IIRDs; to introduce innovative methods for their early diagnosis and treatment (biological agents, JAK inhibitors, and other cell signaling molecules) and for the prediction of the outcomes of the most severe forms of IIRD; to realize the concept of personified medicine (to investigate the prognostic biomarkers of the efficiency and safety of targeted therapy), to reduce the risk of infectious complications, cardiovascular diseases, cancer, osteoporotic fractures, and other comorbidities.
first_indexed 2024-04-10T02:07:03Z
format Article
id doaj.art-0a4811c7f7a644e6b32368911cf8d302
institution Directory Open Access Journal
issn 1996-7012
2310-158X
language Russian
last_indexed 2025-03-14T08:20:45Z
publishDate 2014-09-01
publisher IMA-PRESS LLC
record_format Article
series Современная ревматология
spelling doaj.art-0a4811c7f7a644e6b32368911cf8d3022025-03-02T13:10:57ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2014-09-01834810.14412/1996-7012-2014-3-4-81856Progress in rheumatology in the early 21st centuryE. L. Nasonov0V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia 34A, Kashirskoe Shosse, Moscow 115522Rheumatoid arthritis (RA), juvenile arthritis, spondyloarthritis, including psoriatic arthritis, systemic lupus erythematosus (SLE), and other systemic connective tissue diseases, are the most severe chronic immunoinflammatory rheumatic diseases (IIRDs) that affect as high as 10% of the population. Substantial progress has been made in the treatment of IIRDs in the 21st century. The current Treat to Target (T2T) strategy for RA is to achieve remission as soon as possible. The main treatment goal is to improve quality of life, by controlling the symptoms of the disease, by preventing joint destruction and dysfunction, and by maintaining social possibilities. The most important way to achieve this goal is to inhibit inflammation and to evaluate the efficiency of treatment, by using the standardized activity indices and by choosing the appropriate treatment option. The widespread use of biological agents in combination with standard disease-modifying antirheumatic drugs could substantially enhance therapeutic effectiveness. A new class of medicaments (chemically synthesized small molecular weight agents) to treat RA has appeared. The point of their application is tyrosine kinases, primarily Janus kinase (JAK). The new era in the treatment of SLE and other IIRDs is associated with the design of the new class of drugs Р BLyS inhibitors. In the coming years, the main lines of researches by Russian rheumatologists will be to elaborate a strategy to prevent IIRDs; to introduce innovative methods for their early diagnosis and treatment (biological agents, JAK inhibitors, and other cell signaling molecules) and for the prediction of the outcomes of the most severe forms of IIRD; to realize the concept of personified medicine (to investigate the prognostic biomarkers of the efficiency and safety of targeted therapy), to reduce the risk of infectious complications, cardiovascular diseases, cancer, osteoporotic fractures, and other comorbidities.https://mrj.ima-press.net/mrj/article/view/555immunoinflammatory rheumatic diseasespharmacotherapybiological agentsdisease-modifying antirheumatic drugsjak inhibitorsblys inhibitors
spellingShingle E. L. Nasonov
Progress in rheumatology in the early 21st century
Современная ревматология
immunoinflammatory rheumatic diseases
pharmacotherapy
biological agents
disease-modifying antirheumatic drugs
jak inhibitors
blys inhibitors
title Progress in rheumatology in the early 21st century
title_full Progress in rheumatology in the early 21st century
title_fullStr Progress in rheumatology in the early 21st century
title_full_unstemmed Progress in rheumatology in the early 21st century
title_short Progress in rheumatology in the early 21st century
title_sort progress in rheumatology in the early 21st century
topic immunoinflammatory rheumatic diseases
pharmacotherapy
biological agents
disease-modifying antirheumatic drugs
jak inhibitors
blys inhibitors
url https://mrj.ima-press.net/mrj/article/view/555
work_keys_str_mv AT elnasonov progressinrheumatologyintheearly21stcentury